FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2457-2471 June 14, 2007 Number 24 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Psaty, B. M. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

ABSTRACT

Background Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined.

Methods We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinical-trials registry maintained by the drug manufacturer (GlaxoSmithKline). Criteria for inclusion in our meta-analysis included a study duration of more than 24 weeks, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes. Of 116 potentially relevant studies, 42 trials met the inclusion criteria. We tabulated all occurrences of myocardial infarction and death from cardiovascular causes.

Results Data were combined by means of a fixed-effects model. In the 42 trials, the mean age of the subjects was approximately 56 years, and the mean baseline glycated hemoglobin level was approximately 8.2%. In the rosiglitazone group, as compared with the control group, the odds ratio for myocardial infarction was 1.43 (95% confidence interval [CI], 1.03 to 1.98; P=0.03), and the odds ratio for death from cardiovascular causes was 1.64 (95% CI, 0.98 to 2.74; P=0.06).

Conclusions Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. Our study was limited by a lack of access to original source data, which would have enabled time-to-event analysis. Despite these limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes.

Source Information

From the Cleveland Clinic, Cleveland.

This article (10.1056/NEJMoa072761) was published at www.nejm.org on May 21, 2007.

Address reprint requests to Dr. Nissen at the Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Ave., Cleveland, OH 44195, or at nissens{at}ccf.org.

Full Text of this Article

Related Letters:

Rosiglitazone and Cardiovascular Risk
Bracken M. B., Mannucci E., Monami M., Marchionni N., Diamond G. A., Kaul S., Brett A. S., Nissen S. E., Wolski K., Psaty B. M., Furberg C. D.
Extract | Full Text | PDF  
N Engl J Med 2007; 357:937-940, Aug 30, 2007. Correspondence

This article has been cited by other articles:

• Hemmingsen, B., Lund, S. S, Wetterslev, J., Vaag, A. (2009). Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. Eur J Endocrinol 161: 1-9 [Abstract] [Full Text]  
• Yang, L., Luo, H., Chen, J., Xing, Q., He, L. (2009). SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome. Nucleic Acids Res 37: W406-W412 [Abstract] [Full Text]  
• Jones, A., Deb, R., Torsney, E., Howe, F., Dunkley, M., Gnaneswaran, Y., Gaze, D., Nasr, H., Loftus, I. M., Thompson, M. M., Cockerill, G. W. (2009). Rosiglitazone Reduces the Development and Rupture of Experimental Aortic Aneurysms. Circulation 119: 3125-3132 [Abstract] [Full Text]  
• Allen, L. A., Hernandez, A. F., O'Connor, C. M., Felker, G. M. (2009). End points for clinical trials in acute heart failure syndromes.. J Am Coll Cardiol 53: 2248-2258 [Abstract] [Full Text]  
• The BARI 2D Study Group, (2009). A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. NEJM 360: 2503-2515 [Abstract] [Full Text]  
• Lonn, E. M., Gerstein, H. C., Sheridan, P., Smith, S., Diaz, R., Mohan, V., Bosch, J., Yusuf, S., Dagenais, G. R., DREAM (Diabetes REduction Assessment with ramipril, (2009). Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in People With Impaired Glucose Tolerance or Impaired Fasting Glucose STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).. J Am Coll Cardiol 53: 2028-2035 [Abstract] [Full Text]  
• St. Onge, E. L., Miller, S. A., Taylor, J. R. (2009). Novel Approaches to the Treatment of Type 2 Diabetes. Journal of Pharmacy Practice 22: 320-332 [Abstract]  
• Takagi, T., Okura, H., Kobayashi, Y., Kataoka, T., Taguchi, H., Toda, I., Tamita, K., Yamamuro, A., Sakanoue, Y., Ito, A., Yanagi, S., Shimeno, K., Waseda, K., Yamasaki, M., Fitzgerald, P. J., Ikeno, F., Honda, Y., Yoshiyama, M., Yoshikawa, J., for the POPPS Investigators, (2009). A Prospective, Multicenter, Randomized Trial to Assess Efficacy of Pioglitazone on In-Stent Neointimal Suppression in Type 2 Diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). J Am Coll Cardiol Intv 2: 524-531 [Abstract] [Full Text]  
• Nissen, S. E. (2009). Pioglitazone to Reduce Restenosis After Bare-Metal Stent Placement?. J Am Coll Cardiol Intv 2: 532-533 [Full Text]  
• Hall, G. M., Nicholson, G. (2009). Current Therapeutic Drugs for Type 2 Diabetes, Still Useful After 50 Years?. Anesth. Analg. 108: 1727-1730 [Full Text]  
• Nakaya, H., Summers, B. D., Nicholson, A. C., Gotto, A. M. Jr., Hajjar, D. P., Han, J. (2009). Atherosclerosis in LDLR-Knockout Mice Is Inhibited, but Not Reversed, by the PPAR{gamma} Ligand Pioglitazone. Am. J. Pathol. 174: 2007-2014 [Abstract] [Full Text]  
• Aronson, J. (2009). When I Use a word ... Changing your practice. QJM 0: hcp055v1-hcp055 [Full Text]  
• Banarer, S., Luan, F. L., Duckworth, W. C., Moritz, T., Abraira, C. (2009). Glucose Control and Vascular Complications in Type 2 Diabetes. NEJM 360: 2031-2032 [Full Text]  
• Szeto, C.-C., Chow, K.-M. (2009). THIAZOLIDINEDIONES IN PERITONEAL DIALYSIS PATIENTS. pdi 29: 248-251 [Full Text]  
• Gellad, W. F., Detsky, A. S., Choudhry, N. K. (2009). Implications of recent clinical trials on pay-for-performance. Am J Health Syst Pharm 66: 864-867 [Full Text]  
• Nathan, D. M., for the American Diabetes Association and European, (2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes: Response to Cobitz and Ambery. Diabetes Care 32: e59-e59 [Full Text]  
• Ramirez, S. P.B., Albert, J. M., Blayney, M. J., Tentori, F., Goodkin, D. A., Wolfe, R. A., Young, E. W., Bailie, G. R., Pisoni, R. L., Port, F. K. (2009). Rosiglitazone Is Associated with Mortality in Chronic Hemodialysis Patients. J. Am. Soc. Nephrol. 20: 1094-1101 [Abstract] [Full Text]  
• Flaherty, M. L., Adeoye, O., Sekar, P., Haverbusch, M., Moomaw, C. J., Tao, H., Broderick, J. P., Woo, D. (2009). The Challenge of Designing a Treatment Trial for Warfarin-Associated Intracerebral Hemorrhage. Stroke 40: 1738-1742 [Abstract] [Full Text]  
• Brice, R. (2009). A taxi driver with type 2 diabetes. BMJ 338: b1369-b1369 [Full Text]  
• Morrow, D. A., Scirica, B. M., Chaitman, B. R., McGuire, D. K., Murphy, S. A., Karwatowska-Prokopczuk, E., McCabe, C. H., Braunwald, E., for the MERLIN-TIMI 36 Investigators, (2009). Evaluation of the Glycometabolic Effects of Ranolazine in Patients With and Without Diabetes Mellitus in the MERLIN-TIMI 36 Randomized Controlled Trial. Circulation 119: 2032-2039 [Abstract] [Full Text]  
• Evans-Molina, C., Robbins, R. D., Kono, T., Tersey, S. A., Vestermark, G. L., Nunemaker, C. S., Garmey, J. C., Deering, T. G., Keller, S. R., Maier, B., Mirmira, R. G. (2009). Peroxisome Proliferator-Activated Receptor {gamma} Activation Restores Islet Function in Diabetic Mice through Reduction of Endoplasmic Reticulum Stress and Maintenance of Euchromatin Structure. Mol. Cell. Biol. 29: 2053-2067 [Abstract] [Full Text]  
• Vanasse, A., Carpentier, A. C., Courteau, J., Asghari, S. (2009). Stroke and cardiovascular morbidity and mortality associated with rosiglitazone use in elderly diabetic patients. Diabetes and Vascular Disease Research 6: 87-93 [Abstract]  
• Olin, J. L., Spooner, L. M. (2009). Introduction: Cardiovascular Therapeutics. Journal of Pharmacy Practice 22: 133-134  
• Cheng, J. W. M., Bhatt, S. H., Goldman-Levine, J. D. (2009). The Benefit and Risk of Antidiabetic Agents Used in Patients With Heart Disease. Journal of Pharmacy Practice 22: 179-193 [Abstract]  
• Flory, J. H., Ellenberg, S., Szapary, P. O., Strom, B. L., Hennessy, S. (2009). Antidiabetic Action of Bezafibrate in a Large Observational Database. Diabetes Care 32: 547-551 [Abstract] [Full Text]  
• Meredith, D., Panchatcharam, M., Miriyala, S., Tsai, Y.-S., Morris, A. J., Maeda, N., Stouffer, G. A., Smyth, S. S. (2009). Dominant-Negative Loss of PPAR{gamma} Function Enhances Smooth Muscle Cell Proliferation, Migration, and Vascular Remodeling. Arterioscler. Thromb. Vasc. Bio. 29: 465-471 [Abstract] [Full Text]  
• Mathieu, P., Poirier, P., Pibarot, P., Lemieux, I., Despres, J.-P. (2009). Visceral Obesity: The Link Among Inflammation, Hypertension, and Cardiovascular Disease. Hypertension 53: 577-584 [Full Text]  
• Campbell, I. W (2009). Review: Durable glycaemia -- the promised land. British Journal of Diabetes & Vascular Disease 9: 53-63 [Abstract]  
• Song, S. H, Gray, T. A (2009). Management of type 2 diabetes and lipids: a critique of the NICE guidelines 2008. British Journal of Diabetes & Vascular Disease 9: 69-74 [Abstract]  
• Koh, K. K., Oh, P. C., Quon, M. J. (2009). Does reversal of oxidative stress and inflammation provide vascular protection?. Cardiovasc Res 81: 649-659 [Abstract] [Full Text]  
• Wood, A. J.J. (2009). Progress and Deficiencies in the Registration of Clinical Trials. NEJM 360: 824-830 [Full Text]  
• Horton, E. S. (2009). Defining the role of basal and prandial insulin for optimal glycemic control.. J Am Coll Cardiol 53: S21-S27 [Abstract] [Full Text]  
• HOOGWERF, B. J. (2009). IN REPLY:. Cleveland Clinic Journal of Medicine 76: 83-84 [Full Text]  
• Haneda, M., Morikawa, A. (2009). Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?. Nephrol Dial Transplant 24: 338-341 [Full Text]  
• Havas, S. (2009). The ACCORD Trial and Control of Blood Glucose Level in Type 2 Diabetes Mellitus: Time to Challenge Conventional Wisdom. Arch Intern Med 169: 150-154 [Full Text]  
• Loke, Y. K. MBBS MD, Singh, S. MD MPH, Furberg, C. D. MD PhD (2009). Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 180: 32-39 [Abstract] [Full Text]  
• Lipscombe, L. L. MD MSc (2009). Thiazolidinediones: Do harms outweigh benefits?. CMAJ 180: 16-17 [Full Text]  
• Lindsey, J. B, Cipollone, F., Abdullah, S. M, Mcguire, D. K (2009). Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diabetes and Vascular Disease Research 6: 7-14 [Abstract]  
• van Hooland, S., Boey, O., Van der Niepen, P., Van den Branden, C., Verbeelen, D. (2009). Effect of Short-Term Rosiglitazone Therapy in Peritoneal Dialysis Patients. pdi 29: 108-111 [Full Text]  
• Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B. (2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Clin. Diabetes 27: 4-16 [Full Text]  
• Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B. (2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Spectr. 22: 6-17 [Full Text]  
• Ondrey, F. (2009). Peroxisome Proliferator-Activated Receptor {gamma} Pathway Targeting in Carcinogenesis: Implications for Chemoprevention. Clin. Cancer Res. 15: 2-8 [Abstract] [Full Text]  
• Joy, M. S., Gipson, D. S., Dike, M., Powell, L., Thompson, A., Vento, S., Eddy, A., Fogo, A. B., Kopp, J. B., Cattran, D., Trachtman, H. (2009). Phase I Trial of Rosiglitazone in FSGS: I. Report of the FONT Study Group. CJASN 4: 39-47 [Abstract] [Full Text]  
• Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B. (2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32: 193-203 [Abstract] [Full Text]  
• Jenkins, D. J. A., Kendall, C. W. C., McKeown-Eyssen, G., Josse, R. G., Silverberg, J., Booth, G. L., Vidgen, E., Josse, A. R., Nguyen, T. H., Corrigan, S., Banach, M. S., Ares, S., Mitchell, S., Emam, A., Augustin, L. S. A., Parker, T. L., Leiter, L. A. (2008). Effect of a Low-Glycemic Index or a High-Cereal Fiber Diet on Type 2 Diabetes: A Randomized Trial. JAMA 300: 2742-2753 [Abstract] [Full Text]  
• Michaelson, J. (2008). Thiazolidinedione associated volume overload and pulmonary hypertension. Ther Adv Cardiovasc Dis 2: 435-438 [Abstract]  
• Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., Eckel, R. H. (2008). The Metabolic Syndrome. Endocr. Rev. 29: 777-822 [Abstract] [Full Text]  
• Beysen, C., Murphy, E. J., Nagaraja, H., Decaris, M., Riiff, T., Fong, A., Hellerstein, M. K., Boyle, P. J. (2008). A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes. J. Lipid Res. 49: 2657-2663 [Abstract] [Full Text]  
• Winkelmayer, W. C., Setoguchi, S., Levin, R., Solomon, D. H. (2008). Comparison of Cardiovascular Outcomes in Elderly Patients With Diabetes Who Initiated Rosiglitazone vs Pioglitazone Therapy. Arch Intern Med 168: 2368-2375 [Abstract] [Full Text]  
• Von Bibra, H., Diamant, M., Scheffer, P. G, Siegmund, T., Schumm-Draeger, P.-M. (2008). Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease. Diabetes and Vascular Disease Research 5: 310-318 [Abstract]  
• Shah, A., Mehta, N., Reilly, M. P. (2008). Adipose Inflammation, Insulin Resistance, and Cardiovascular Disease. JPEN J Parenter Enteral Nutr 32: 638-644 [Abstract] [Full Text]  
• Chitturi, S. (2008). Review: Treatment options for nonalcoholic fatty liver disease. Therapeutic Advances in Gastroenterology 1: 173-189 [Abstract]  
• Hausenloy, D J, Yellon, D M (2008). Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Postgrad. Med. J. 84: 590-598 [Abstract] [Full Text]  
• Pinelli, N. R, Cha, R., Brown, M. B, Jaber, L. A (2008). Addition of Thiazolidinedione or Exenatide to Oral Agents in Type 2 Diabetes: A Meta-Analysis. The Annals of Pharmacotherapy 42: 1541-1551 [Abstract] [Full Text]  
• Nathan, D. M. (2008). Glycemic Management of Type 2 Diabetes: How Tight Is Right and How to Get There. Arch Intern Med 168: 2064-2066 [Full Text]  
• Selvin, E., Bolen, S., Yeh, H.-C., Wiley, C., Wilson, L. M., Marinopoulos, S. S., Feldman, L., Vassy, J., Wilson, R., Bass, E. B., Brancati, F. L. (2008). Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review. Arch Intern Med 168: 2070-2080 [Abstract] [Full Text]  
• Alexander, G. C., Sehgal, N. L., Moloney, R. M., Stafford, R. S. (2008). National Trends in Treatment of Type 2 Diabetes Mellitus, 1994-2007. Arch Intern Med 168: 2088-2094 [Abstract] [Full Text]  
• Ho, P. M., Peterson, P. N., Masoudi, F. A. (2008). Evaluating the Evidence: Is There a Rigid Hierarchy?. Circulation 118: 1675-1684 [Full Text]  
• Jenny-Avital, E. R., Luan, F. L., Nguyen, K., Tobey, T. A., Parashar, A., Byington, R. P., Gerstein, H. C., Friedewald, W. T., Patel, A., MacMahon, S., Chalmers, J. (2008). Intensive Glucose Control in Type 2 Diabetes. NEJM 359: 1519-1521 [Full Text]  
• HOOGWERF, B. J. (2008). Does intensive therapy of type 2 diabetes help or harm? Seeking accord on ACCORD. Cleveland Clinic Journal of Medicine 75: 729-737 [Abstract] [Full Text]  
• Odom, J., Williamson, B., Carter, L. (2008). Rosiglitazone and pioglitazone in the treatment of diabetes mellitus. Am J Health Syst Pharm 65: 1846-1850 [Full Text]  
• Mallewa, J. E., Wilkins, E., Vilar, J., Mallewa, M., Doran, D., Back, D., Pirmohamed, M. (2008). HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options. J Antimicrob Chemother 62: 648-660 [Abstract] [Full Text]  
• Johnson, E. L., Brosseau, J. D., Soule, M., Kolberg, J. (2008). Treatment of Diabetes in Long-Term Care Facilities: A Primary Care Approach. Clin. Diabetes 26: 152-156 [Abstract] [Full Text]  
• Rosenzweig, J. L., Ferrannini, E., Grundy, S. M., Haffner, S. M., Heine, R. J., Horton, E. S., Kawamori, R. (2008). Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 93: 3671-3689 [Abstract] [Full Text]  
• Kahn, S. E., Cefalu, W. T. (2008). Glucose Control, Macro- and Microvascular Disease, and the Food and Drug Administration: Let's Keep Our Eye on the Ball. J. Clin. Endocrinol. Metab. 93: 3727-3729 [Full Text]  
• Srinivasan, B T, Jarvis, J, Khunti, K, Davies, M J (2008). Recent advances in the management of type 2 diabetes mellitus: a review. Postgrad. Med. J. 84: 524-531 [Abstract] [Full Text]  
• Khanderia, U., Pop-Busui, R., Eagle, K. A (2008). Thiazolidinediones in Type 2 Diabetes: A Cardiology Perspective. The Annals of Pharmacotherapy 42: 1466-1474 [Abstract] [Full Text]  
• Kittisupamongkol, W. (2008). Effect of Folic Acid and B Vitamins on Cardiovascular Disease in Women. JAMA 300: 1410-1410 [Full Text]  
• Nallamothu, B. K., Hayward, R. A., Bates, E. R. (2008). Beyond the Randomized Clinical Trial: The Role of Effectiveness Studies in Evaluating Cardiovascular Therapies. Circulation 118: 1294-1303 [Full Text]  
• Beyer, A. M., de Lange, W. J., Halabi, C. M., Modrick, M. L., Keen, H. L., Faraci, F. M., Sigmund, C. D. (2008). Endothelium-Specific Interference With Peroxisome Proliferator Activated Receptor Gamma Causes Cerebral Vascular Dysfunction in Response to a High-Fat Diet. Circ. Res. 103: 654-661 [Abstract] [Full Text]  
• Goldfine, A. B. (2008). Assessing the Cardiovascular Safety of Diabetes Therapies. NEJM 359: 1092-1095 [Full Text]  
• Fuller, J. (2008). A 39-Year-Old Man With HIV-Associated Lipodystrophy. JAMA 300: 1056-1066 [Abstract] [Full Text]  
• Orasanu, G., Ziouzenkova, O., Devchand, P. R., Nehra, V., Hamdy, O., Horton, E. S., Plutzky, J. (2008). The Peroxisome Proliferator-Activated Receptor-{gamma} Agonist Pioglitazone Represses Inflammation in a Peroxisome Proliferator-Activated Receptor-{alpha}-Dependent Manner In Vitro and In Vivo in Mice. J Am Coll Cardiol 52: 869-881 [Abstract] [Full Text]  
• Kintscher, U. (2008). Pharmacological Differences of Glitazones: Does Peroxisome Proliferator-Activated Receptor-{alpha} Activation Make the Difference?. J Am Coll Cardiol 52: 882-884 [Full Text]  
• Matthews, D. R, Tsapas, A., Tsapas, A. (2008). Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes. Diabetes and Vascular Disease Research 5: 216-218  
• Bloomgarden, Z. T. (2008). Glycemic Control in Diabetes: A Tale of Three Studies. Diabetes Care 31: 1913-1919 [Full Text]  
• Psaty, B. M., Vandenbroucke, J. P. (2008). Opportunities for Enhancing the FDA Guidance on Pharmacovigilance. JAMA 300: 952-954 [Full Text]  
• Lu, Z., Sack, M. N. (2008). ATF-1 Is a Hypoxia-responsive Transcriptional Activator of Skeletal Muscle Mitochondrial-uncoupling Protein 3. J. Biol. Chem. 283: 23410-23418 [Abstract] [Full Text]  
• Pagel-Langenickel, I., Bao, J., Joseph, J. J., Schwartz, D. R., Mantell, B. S., Xu, X., Raghavachari, N., Sack, M. N. (2008). PGC-1{alpha} Integrates Insulin Signaling, Mitochondrial Regulation, and Bioenergetic Function in Skeletal Muscle. J. Biol. Chem. 283: 22464-22472 [Abstract] [Full Text]  
• Romero, J. R., Morris, J., Pikula, A. (2008). Review: Stroke prevention: modifying risk factors. Ther Adv Cardiovasc Dis 2: 287-303 [Abstract]  
• Brown, T. T. (2008). Approach to the Human Immunodeficiency Virus-Infected Patient with Lipodystrophy. J. Clin. Endocrinol. Metab. 93: 2937-2945 [Abstract] [Full Text]  
• Bloomgarden, Z. T. (2008). Approaches to Treatment of Type 2 Diabetes. Diabetes Care 31: 1697-1703 [Full Text]  
• Lehmann, D. F., Lohray, B. B. (2008). A Lesson in Moderation: Applying Pharmacodynamics to Clarify the Relationship Between Thiazolidinediones and Adverse Vascular Outcomes in Type 2 Diabetes. J Clin Pharmacol 48: 999-1002 [Full Text]  
• Rao, A. D., Kuhadiya, N., Reynolds, K., Fonseca, V. A. (2008). Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?: A meta-analysis of observational studies. Diabetes Care 31: 1672-1678 [Abstract] [Full Text]  
• Blaha, M. J., Bansal, S., Rouf, R., Golden, S. H., Blumenthal, R. S., DeFilippis, A. P. (2008). A Practical 'ABCDE' Approach to the Metabolic Syndrome. Mayo Clin Proc. 83: 932-943 [Abstract] [Full Text]  
• Li, Y., Kovach, A., Suino-Powell, K., Martynowski, D., Xu, H. E. (2008). Structural and Biochemical Basis for the Binding Selectivity of Peroxisome Proliferator-activated Receptor {gamma} to PGC-1{alpha}. J. Biol. Chem. 283: 19132-19139 [Abstract] [Full Text]  
• Davies, M. (2008). Focus on glycaemic management: A veritable feast or a dog's dinner?. British Journal of Diabetes & Vascular Disease 8: 191-194 [Abstract]  
• Triplitt, C., Alvarez, C. A. (2008). Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes. Diabetes Spectr. 21: 177-189 [Abstract] [Full Text]  
• Szocs, Z., Brunmair, B., Stadlbauer, K., Nowotny, P., Bauer, L., Luger, A., Furnsinn, C. (2008). Age-Dependent Development of Metabolic Derangement and Effects of Intervention with Pioglitazone in Zucker Diabetic Fatty Rats. J. Pharmacol. Exp. Ther. 326: 323-329 [Abstract] [Full Text]  
• Monami, M., Lamanna, C., Marchionni, N., Mannucci, E. (2008). Rosiglitazone and Risk of Cancer: A meta-analysis of randomized clinical trials. Diabetes Care 31: 1455-1460 [Abstract] [Full Text]  
• Abaterusso, C., Lupo, A., Ortalda, V., De Biase, V., Pani, A., Muggeo, M., Gambaro, G. (2008). Treating Elderly People with Diabetes and Stages 3 and 4 Chronic Kidney Disease. CJASN 3: 1185-1194 [Abstract] [Full Text]  
• Dluhy, R. G., McMahon, G. T. (2008). Intensive Glycemic Control in the ACCORD and ADVANCE Trials. NEJM 358: 2630-2633 [Full Text]